- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13.11. | High-flying Metsera follows phase 1 weight loss data with $215M series B raise | ||
| 13.11. | Ovid pauses phase 2 plans for ROCK2 inhibitor to mull mixed data from Recursion's rival drug | ||
| 13.11. | Sanofi, Formation and OpenAI design AI tool to slash clinical trial timelines | ||
| 13.11. | BioNTech pays $800M to take control of potential Keytruda killer | ||
| 13.11. | Hidden data on obesity prospect wipe $12B off Amgen market cap | ||
| 13.11. | FDA hits Kezar's zetomipzomib program with 2nd clinical hold in 2 months | ||
| 12.11. | Syndax's small molecule underwhelms investors in midstage acute leukemia trial, sending stock down 22% | ||
| 12.11. | Insilico's AI-designed med tied to respiratory health improvements in midstage lung disease trial | ||
| 12.11. | J&J gets FDA thumbs-up to begin clinical trials for its Ottava surgical robot | ||
| 12.11. | Bayer drops Huntington's gene therapy to focus on 'most promising assets' | ||
| 12.11. | Centessa drops phase 2 hemophilia B drug in wake of Pfizer's Hympavzi approval | ||
| 12.11. | Novartis pays Schrödinger $150M, bets billions on the back end to form drug discovery pact | ||
| 12.11. | Novo Holdings, OrbiMed, Jeito lead $181M fundraise for ADC biotech | ||
| 12.11. | AstraZeneca, Daiichi withdraw lung cancer approval application for Enhertu follow-up and try again | ||
| 12.11. | Merck KGaA's phase 3 rare tumor trial hits goal, teeing up rivalry with Daiichi and Ono | ||
| 12.11. | 23andMe shutters cancer drug research programs, lays off 40% of staff | ||
| 11.11. | MD Anderson Cancer Center unveils cell therapy research institute that will work with biotech, pharma | ||
| 11.11. | AbbVie's $9B schizophrenia prospect flunks phase 2 trials, handing advantage to BMS | ||
| 11.11. | Rapt sees share price halve after shelving immunology drug under FDA hold | ||
| 11.11. | Evotec, after stock-tanking blows, attracts private equity buyout interest: report | ||
| 11.11. | Ideaya pushes ahead with Biocytogen bispecific ADC bet | ||
| 08.11. | In 'surprise' termination, Genentech drops Nykode partnership for individualized cancer vaccine | ||
| 08.11. | What medtech CEOs are saying this week about Trump's potential tariffs | ||
| 08.11. | Dynavax drops Tdap vaccine after considering phase 1 data, competition | ||
| 08.11. | Struggling AlloVir finds new identity by merging into eye disease biotech |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
